Roche’s Gazyva shows strong phase III results for treatment of idiopathic nephrotic syndrome

Key secondary endpoints also demonstrated statistically significant and clinically meaningful benefits with Gazyva

Lilly and NVIDIA join forces to build world’s most powerful AI supercomputer for drug discovery

New AI capabilities will help scientists identify, optimize, and validate new molecules. Additional applications include manufacturing, medical imaging, and enterprise AI agents

FDA approves Bayer’s Lynkuet as first hormone-free therapy for menopausal hot flashes

This approval marks a significant milestone in women’s health, introducing Bayer’s first hormone-free treatment for menopause-related symptoms

Elixion Biotech takes quantum-informed R&D route for next-gen precision medicines

MIRA Pharmaceuticals advances oral Ketamir-2 into Phase 1 MAD study for chemotherapy-induced neuropathic pain

Advancing toward Phase 2a evaluation in chemotherapy-related pain, a condition with no approved treatments and potential for FDA Fast Track designation

Medherant announces positive Phase 1 results of clinical trial of testosterone patch for women

Medherant’s testosterone TEPI Patch could become the first-in-class testosterone patch developed specifically for women

FDA approves Alembic's Ticagrelor Tablets, 60 mg

Ticagrelor tablets are indicated for reducing the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients

Sai Life Sciences to double process R&D capacity with new facility in Hyderabad

The new CMC Process R&D Center represents a strategic investment in scale, sustainability, and specialization

MilliporeSigma partners with Promega to advance 3-D cell drug discovery technologies

Partnership combines MilliporeSigma’s chemistry and organoid expertise with Promega’s assay technologies

Zydus receives approval from Health Canada for Mesalamine suppositories

Mesalamine suppositories are indicated for the treatment of mildly to moderately active ulcerative proctitis